When to refer patients with MPN to clinical trials: Part II - Patients with MF

The MPN Hub was pleased to speak to Laura Michaelis, Medical College of Wisconsin, Milwaukee, US and Anand Patel, University of Chicago, Chicago, US. We asked, When to refer patients with MPN to clinical trials: Part II - Patients with myelofibrosis (MF).

Patel opens by highlighting the need for more long-term effective MF treatments and presents long-term data on the cessation of existing therapies such as ruxolitinib. Michaelis and Patel then discuss factors that influence the decision to refer to a clinical trial in patients with newly diagnosed MF; outlining anemia and other symptoms as indicators for referral. They also discuss add-on clinical trials as options for patients who do not achieve optimal response with their current standard of care treatment.

The podcast concludes with a discussion on clinical trial referral versus transplantation in patients not achieving an optimal treatment response with standard of care. Finally, the importance of communicating effectively with the patient and considering their comorbidities is highlighted.